Addex TherapeuticsADXN.OValuation Analysis

As of Oct 16, 2026, Addex Therapeutics (ADXN.O) trades at a negative P/E (-0.57x, due to a recent net loss), P/B of 2.05x, P/S of N/A, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 66th percentile over the trailing 10Y window (vs. 85th percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/B ranks at the 46th percentile within its industry and the 59th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Relative to industry peers, its P/B shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Addex Therapeutics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.